Biology Reference
In-Depth Information
[115] Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects
of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overpro-
duction in asthma. Nat Med 2002;8(8):885-9.
[116] Gowdy KM, Nugent JL, Martinu T, Potts E, Snyder LD, Foster WM, et al. Protective role
of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar
fibrosis. Am J Respir Cell Mol Biol 2012;46(2):249-56.
[117] Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, et al. Bone marrow
myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD)
via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood
2010;116(25):5738-47.
[118] Jordan WJ, Brookes PA, Szydlo RM, Goldman JM, Lechler RI, Ritter MA. IL-13 produc-
tion by donor T cells is prognostic of acute graft-versus-host disease following unre-
lated donor stem cell transplantation. Blood 2004;103(2):717-24.
[119] Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignan-
cies. Blood 2006;107(12):4589-96.
[120] Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+
T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature
1997;389(6652):737-42.
[121] Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a platelet-derived trans-
forming growth factor. Proc Natl Acad Sci U S A 1982;79(17):5312-6.
[122] Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, Narula S,
et al. IL-10 and TGF-beta induce alloreactive CD4+CD25− T cells to acquire regulatory
cell function. Blood 2003;101(12):5076-83.
[123] Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immu-
nol 2002;2(1):46-53.
[124] Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, Ruscetti FW, Narula S, Roncarolo MG,
et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and
TGF-beta. J Immunol 1999;163(7):3684-91.
[125] Zheng SG, Wang JH, Koss MN, Quismorio Jr F, Gray JD, Horwitz DA. CD4+ and CD8+
regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory
graft-versus-host disease with a lupus-like syndrome. J Immunol 2004;172(3):1531-9.
[126] Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, et al. TGF-beta in alloge-
neic stem cell transplantation: friend or foe?. Blood 2005;106(6):2206-14.
[127] Remberger M, Jaksch M, Uzunel M, Mattsson J. Serum levels of cytokines correlate to
donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell trans-
plantation. Eur J Haematol 2003;70(6):384-91.
[128] Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130.
Blood 1995;86(4):1243-54.
[129] Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines.
Science 1992;258(5082):593-7.
[130] Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory
properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813(5):878-88.
[131] Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F.
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J
2003;374(Pt 1):1-20.
[132] Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, et al. Blockade of inter-
leukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity
of graft-versus-host disease. Blood 2009;114(4):891-900.
[133] Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, et al. Interleukin-6 modulates
graft-versus-host responses after experimental allogeneic bone marrow transplanta-
tion. Clin Cancer Res 2011;17(1):77-88.
[134] Ambruzova Z, Mrazek F, Raida L, Jindra P, Vidan-Jeras B, Faber E, et al. Association of
IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic
stem cell transplantation. Bone Marrow Transplant 2009;44(4):227-35.
[135] Socie G, Loiseau P, Tamouza R, Janin A, Busson M, Gluckman E, et al. Both genetic and
clinical factors predict the development of graft-versus-host disease after allogeneic
hematopoietic stem cell transplantation. Transplantation 2001;72(4):699-706.
[136] Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-
gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease
in HLA-matched sibling bone marrow transplantation. Blood 2001;98(5):1594-600.
[137] Gergis U, Arnason J, Yantiss R, Shore T, Wissa U, Feldman E, et al. Effectiveness and
safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient
with refractory GI graft-versus-host disease. J Clin Oncol 2010;28(30):e602-4.
[138] Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, et al. Tocili-
zumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood
Marrow Transplant 2011;17(12):1862-8.
387
Search WWH ::
Custom Search